Bioventus Inc.
BVS · NASDAQ
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $446 | $450 | $596 | $687 |
| - Cash | $42 | $33 | $23 | $42 |
| + Debt | $11 | $341 | $346 | $336 |
| Enterprise Value | $415 | $759 | $919 | $981 |
| Revenue | $139 | $148 | $124 | $154 |
| % Growth | -6.1% | 19.2% | -19.4% | – |
| Gross Profit | $93 | $102 | $83 | $103 |
| % Margin | 67% | 69.1% | 67% | 66.8% |
| EBITDA | $22 | $30 | $16 | $22 |
| % Margin | 16% | 20.2% | 12.9% | 14.1% |
| Net Income | $3 | $7 | -$3 | -$0 |
| % Margin | 2.3% | 5.1% | -2.1% | -0.1% |
| EPS Diluted | 0.046 | 0.11 | -0.04 | -0.002 |
| % Growth | -58.4% | 375% | -1,900% | – |
| Operating Cash Flow | $30 | $26 | -$19 | $19 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$1 |
| Free Cash Flow | $30 | $25 | -$20 | $19 |